Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the adequacy of the supply of GLP1 medication.

The Department of Health and Social Care has worked intensively with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency (MHRA) and others in the supply chain to largely resolve the supply issues with GLP-1 receptor agonists (GLP-1 RAs). Currently, all GLP-1 RA medicines are available for NHS patients. We are aware of a short-term supply issue with one strength of Wegovy FlexTouch injection for private patients which is expected to resolve in mid-September 2025.

We continue to monitor the supply of GLP-1 RAs closely to ensure these medicines remain available. Any patient concerned about their condition, or access to these medications, should speak to their prescriber in the first instance.